Chronic diabetes conditions include type 1 diabetes and type 2 diabetes. Potentially reversible diabetes conditions include prediabetes and gestational diabetes. Prediabetes occurs when your blood sugar levels are higher than normal, but not high enough to be classified as diabetes. And prediabetes is often the precursor of diabetes unless appropriate measures are taken to prevent progression. Gestational diabetes occurs during pregnancy but may resolve after the baby is delivered.
September 4th 2024
Embecta’s new patch pump offers a larger insulin reservoir to better accommodate for the needs of patients with type 2 diabetes (T2D).
Introduction to Chronic Kidney Disease in People Living With Type 2 Diabetes: Combating Disease Progression an...
1.0 Credit / Endocrinology, Diabetes, and Metabolism, Nephrology
View More
Examining Current and Emerging Therapies to Slow Progression of Chronic Kidney Disease
1.0 Credit / Endocrinology, Diabetes, and Metabolism, Nephrology
View More
Best Practices for the Integration of Continuous Glucose Monitoring Devices Across Community Pharmacy Settings
September 24, 2024 | 1:00 PM ET
View More
Tailoring Recommendations for People Living With Type 2 Diabetes and Chronic Kidney Disease: The Role of the P...
1.0 Credit / Endocrinology, Diabetes, and Metabolism, Nephrology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
The Utilization of SGLT2 Inhibitors in the Treatment of Cardiovascular Disease, Diabetes, and Chronic Kidney D...
1.5 Credits / Cardiology; Endocrinology, Diabetes & Metabolism; Nephrology
View More
Integrated Continuous Glucose Monitoring Implementation and Connectivity: Best Practices, Featuring a Powered ...
1.5 Credit / Endocrinology, Diabetes & Metabolism
View More
Integrated Continuous Glucose Monitoring Implementation and Connectivity: Best Practices, Featuring a Powered ...
1.5 Credit / Endocrinology, Diabetes & Metabolism
View More
Reducing Barriers in Integrated Continuous Glucose Monitoring Use, Featuring Patient Counseling Video Vignette...
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Reducing Barriers in Integrated Continuous Glucose Monitoring Use, Featuring Patient Counseling Video Vignette...
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Integrated Continuous Glucose Monitoring: What’s New in 2024, Featuring a Device Demonstration and Patient Cou...
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Integrated Continuous Glucose Monitoring: What’s New in 2024, Featuring a Device Demonstration and Patient Cou...
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Strategies for Addressing Cardiovascular Disease, Diabetes, and Chronic Kidney Disease With SGLT2 Inhibitors
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Reducing Endocrinopathies of Immune Checkpoint Inhibitor Therapy: Management Strategies for Oncology Pharmacis...
1.0 Credit / Oncology, Endocrinology, Diabetes & Metabolism
View More
Foundations in Continuous Glucose Monitoring
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
SimulatED: Using Continuous Glucose Monitoring Data to Improve Health Outcomes
0.75 Credit / Endocrinology, Diabetes & Metabolism
View More
SimulatED: Using Continuous Glucose Monitoring Data to Improve Health Outcomes (Pharmacy Technician Credit)
0.75 Credit / Endocrinology, Diabetes & Metabolism
View More
Uncovering the Challenges in Treatment Pathways in AMD and DME
1.0 Credit / Endocrinology, Diabetes & Metabolism, Ophthalmology & Optometry
View More
Navigating Anti-Vascular Endothelial Growth Factor Therapy and Dosing Strategies
1.0 Credit / Endocrinology, Diabetes & Metabolism, Ophthalmology & Optometry
View More
Improving Patient Outcomes in AMD and DME Through the Integration of Specialty Pharmacy Care
1.0 Credit / Endocrinology, Diabetes & Metabolism, Ophthalmology & Optometry
View More
Best Practices for the Integration of Continuous Glucose Monitoring Within the Health System
1.5 Credits / Endocrinology, Diabetes & Metabolism
View More
Phase 3 Trial Shows Benefit of Empagliflozin for Pediatric Type 2 Diabetes
December 22nd 2022Eli Lilly and Company and Boehringer Ingelheim announced their SGLT2 inhibitor, empagliflozin, was associated with statistically significant reductions in HbA1c relative to placebo therapy among a population of pediatric patients with type 2 diabetes in the DINAMO trial.